Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC

9 Feb 2023

Abstract excerpt

INTRODUCTION: Patient selection for checkpoint inhibitor immunotherapy is currently guided by programmed death-ligand 1 (PD-L1) expression obtained from immunohistochemical staining of tumor tissue samples. This approach is susceptible to limitations resulting from the dynamic and heterogeneous nature of cancer cells and the invasiveness of the tissue sampling procedure. To address these challenges, we developed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Diagnosis and Treatment
Share to Radiomics and Machine Learning in Medical Imaging

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36773776
DOI: 10.1016/j.jtho.2023.01.089

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLCPMID 36773776Read ↗

Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomicsSemantic proximity Read ↗

A radiomics approach to assess tumour-infiltrating CD8 cells and response to anti-PD-1 or anti-PD-L1 immunotherapy: an imaging biomarker, retrospective multicohort study.Semantic proximity Read ↗

Integrated CT-derived radiomics for predicting ctDNA status and prognosis in resectable non-small cell lung cancerSemantic proximity Read ↗

Predicting PD-L1 expression in advanced EGFR-mutant lung adenocarcinoma patients using NECT, CECT radiomics and clinical features.Semantic proximity Read ↗

Towards a Survival Risk Prediction Model for Metastatic NSCLC Patients on Durvalumab Using Whole-Lung CT RadiomicsSemantic proximity Read ↗

Prediction of immunotherapy response using deep learning of PET/CT imagesSemantic proximity Read ↗

Hypoxia-related radiomics predict immunotherapy response: A multi-cohort study of NSCLCSemantic proximity Read ↗

Radiomics and deep learning in lung cancer.Semantic proximity Read ↗

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker.Semantic proximity Read ↗

Radiomicsmetabolic signature profiles for advanced non-small cell lung cancer with chemoimmunotherapy by reflecting biological function and survivalSemantic proximity Read ↗

Non-invasive decision support for NSCLC treatment using PET/CT radiomics.Semantic proximity Read ↗

Radiomic Analysis and Liquid Biopsy in Preoperative CT of NSCLC : An Explorative ExperienceSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.